logo

Dynavax Technologies Corp (DVAX)



Trade DVAX now with
  Date
  Headline
11/9/2017 4:50:35 PM Dynavax Reports FDA Approval Of HEPLISAV-B For Prevention Of Hepatitis B In Adults
11/3/2017 6:40:45 AM Dynavax Technologies Q3 Net Loss Narrows To $22.1 Mln Or $0.38/shr From $34.7 Mln Or $0.90/shr Last Year
9/25/2017 8:59:27 AM RBC Capital Markets Is Raising Dynavax Technologies Corp (DVAX) 4Q18 Estimate To -0.58 From -0.60
9/25/2017 8:59:08 AM RBC Capital Markets Is Lowering Dynavax Technologies Corp (DVAX) 3Q18 Estimate To -0.60 From -0.58
9/25/2017 8:58:53 AM RBC Capital Markets Is Cutting Dynavax Technologies Corp (DVAX) 2Q18 Estimate To -0.56 From -0.54
9/25/2017 8:58:40 AM RBC Capital Markets Is Lowering Dynavax Technologies Corp (DVAX) 1Q18 Estimate To -0.52 From -0.51
9/25/2017 8:58:26 AM RBC Capital Markets Is Cutting Dynavax Technologies Corp (DVAX) 4Q17 Estimate To -0.48 From -0.45
9/25/2017 8:58:09 AM RBC Capital Markets Is Lowering Dynavax Technologies Corp (DVAX) 3Q17 Estimate To -0.44 From -0.33
9/25/2017 8:57:53 AM RBC Capital Markets Is Raising Dynavax Technologies Corp (DVAX) 2017 Estimate To -1.08 From -1.57
9/25/2017 8:57:35 AM RBC Capital Markets Is Cutting Dynavax Technologies Corp (DVAX) 2018 Estimate To -2.27 From -2.23
9/25/2017 8:57:18 AM RBC Capital Markets Is Cutting Dynavax Technologies Corp (DVAX) 2017 Estimate To -1.92 From -1.78
9/25/2017 8:52:43 AM RBC Capital Markets Is Raising Dynavax Technologies Corp (DVAX) 4Q18 Rev. Estimate To 8.8 M From 6.5 M
9/25/2017 8:52:27 AM RBC Capital Markets Is Lowering Dynavax Technologies Corp (DVAX) 3Q18 Rev. Estimate To 3.5 M From 4.0 M
9/25/2017 8:52:17 AM RBC Capital Markets Is Lowering Dynavax Technologies Corp (DVAX) 2Q18 Rev. Estimate To 2.0 M From 2.5 M
9/25/2017 8:51:58 AM RBC Capital Markets Is Cutting Dynavax Technologies Corp (DVAX) 1Q18 Rev. Estimate To 0.5 M From 1.5 M
9/25/2017 8:51:45 AM RBC Capital Markets Is Cutting Dynavax Technologies Corp (DVAX) 4Q17 Rev. Estimate To 0.0 M From 1.0 M